Mini Review
Volume 9:4, 2023

Abnormal and Behavioural Psychology

ISSN: 2472-0496 Open Access

Understanding the Neurobiological Basis of Schizophrenia through the Lens of Abnormal Psychology

Sea Kenne*

Department of Neurology, Tallaght University Hospital, D24NR0A Dublin, Ireland

Abstract

Schizophrenia is a complex and debilitating mental disorder that affects millions of individuals worldwide. Despite significant advancements in research, its exact neurobiological basis remains elusive. This article explores the intricate relationship between abnormal psychology and the neurobiological factors that contribute to the development and manifestation of schizophrenia. By examining the disruptions in neurotransmitter systems, brain structure, and functional connectivity, we aim to gain a deeper understanding of the underlying mechanisms of this disorder. Additionally, the article discusses the potential implications of such insights for the development of more effective diagnostic tools and targeted interventions.

Keywords: Schizophrenia • Mental disorder • Neurotransmitters

Introduction

Schizophrenia is a perplexing mental disorder characterized by a range of symptoms, including hallucinations, delusions, disorganized thinking, and impaired emotional responsiveness. It affects around 1% of the global population and poses substantial challenges to both individuals diagnosed and the healthcare systems. The origins of schizophrenia lie at the intersection of abnormal psychology and neurobiological processes. This article aims to explore the connections between these domains and shed light on how disturbances in neurotransmitter systems, brain structure, and functional connectivity contribute to the development and expression of schizophrenia [1].

Literature Review

Neurotransmitters play a pivotal role in facilitating communication between nerve cells in the brain. Dysregulation of neurotransmitter systems, particularly dopamine, glutamate, and serotonin, has been implicated in the pathophysiology of schizophrenia. The dopamine hypothesis, for instance, posits that excessive dopamine activity in certain brain regions contributes to positive symptoms such as hallucinations and delusions. This hypothesis has driven the development of antipsychotic medications that target dopamine receptors. On the other hand, disruptions in glutamatergic and serotonergic systems are associated with cognitive deficits and negative symptoms of the disorder. Abnormalities in these neurotransmitter systems offer insights into the intricate interplay between neurochemistry and abnormal psychology in schizophrenia [2].

Genetic factors have been widely implicated in the development of schizophrenia. Family, twin, and adoption studies consistently suggest a hereditary component to the disorder. Research has identified multiple susceptibility genes associated with schizophrenia, providing valuable insights into the molecular mechanisms that may contribute to its onset. Notably, these genes often influence crucial neurodevelopmental processes, synaptic function, and neurotransmitter signalling. The advent of Genome-Wide Association Studies (GWAS) has significantly advanced our understanding of the complex genetic landscape of schizophrenia. However, it is important to note that genetic predisposition alone is insufficient to trigger the disorder, emphasizing the necessity of environmental factors in its development [3].

Modern neuroimaging techniques have revealed structural brain abnormalities in individuals with schizophrenia. Studies utilizing Magnetic Resonance Imaging (MRI) have consistently shown altered brain volume, particularly in regions such as the prefrontal cortex, hippocampus, and thalamus. These structural changes are closely linked to the cognitive impairments observed in schizophrenia. For example, the prefrontal cortex is implicated in executive functions and working memory, which are often compromised in individuals with the disorder. Furthermore, abnormalities in the hippocampus contribute to memory deficits, while thalamic irregularities are associated with sensory processing disruptions. By understanding how these structural alterations relate to abnormal psychological symptoms, researchers can potentially develop targeted interventions to alleviate cognitive impairments [4].

Discussion

The brain operates as a network of interconnected regions that communicate to perform various cognitive and emotional functions. Functional connectivity refers to the synchronization of activity between different brain regions. In schizophrenia, disruptions in functional connectivity have been identified through techniques such as functional MRI (fMRI) and Electroencephalography (EEG). These disruptions are thought to underlie the disintegration of thoughts and perceptions observed in the disorder. Abnormal functional connectivity patterns also contribute to deficits in social cognition, making it challenging for individuals with schizophrenia to accurately perceive and interpret social cues. Investigating these connectivity abnormalities from an abnormal psychology perspective can provide valuable insights into the social and cognitive challenges faced by individuals with schizophrenia [5].

The interaction between genetic vulnerability and environmental factors plays a pivotal role in the emergence of schizophrenia. Neurodevelopmental abnormalities, such as prenatal infections, malnutrition, and complications during birth, have been linked to an increased risk of developing the disorder later in life. Early life stressors, such as childhood trauma and urban upbringing, have also been associated with a higher susceptibility to schizophrenia. These environmental triggers can disrupt the delicate balance of neural circuitry and contribute to altered brain development, ultimately influencing the manifestation of symptoms.

The integration of abnormal psychology and neurobiological research has promising implications for the diagnosis and treatment of schizophrenia. Traditional diagnostic criteria are primarily based on observable behaviours and symptoms. However, understanding the underlying neurobiological mechanisms can pave

***Address for Correspondence:** Sea Kenne, Department of Neurology, Tallaght University Hospital, D24NR0A Dublin, Ireland, E-mail: seakenne@gmail.com*

Received: 02 August, 2023, Manuscript No. abp-23-112283; **Editor Assigned:** 04 August, 2023, PreQC No. P-112283; **Reviewed:** 16 August, 2023, QC No. Q-112283; **Revised:** 21 August, 2023, Manuscript No. R-112283; **Published:** 28 August, 2023, DOI: 10.37421/2472-0496.2023.9.211

the way for more accurate and reliable diagnostic tools, such as neuroimaging-based biomarkers. These tools could facilitate early detection and intervention, potentially improving long-term outcomes for individuals with schizophrenia. Furthermore, insights into the neurobiological basis of the disorder can guide the development of novel therapeutic interventions. Targeted treatments that address specific neurotransmitter imbalances or enhance functional connectivity could lead to more effective symptom management. Personalized approaches to treatment could consider an individual's unique neurobiological profile, offering a more tailored and efficient therapeutic strategy [6].

Conclusion

The study of schizophrenia through the lens of abnormal psychology provides a comprehensive framework for understanding the intricate interplay between psychological symptoms and underlying neurobiological processes. Neurotransmitter dysregulation, structural brain abnormalities, and disruptions in functional connectivity collectively contribute to the complex nature of this disorder. As research progresses, the insights gained from these connections hold promise for revolutionizing diagnostic practices and therapeutic interventions, ultimately improving the lives of individuals living with schizophrenia.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Feigin, Valery L., Emma Nichols, Tahiya Alam and Marlena S. Bannick, et al. "Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016." *Lancet Neurol* 18 (2019): 459-480.
2. Castro, Diego M., Carol Dillon, Gerardo Machnicki and Ricardo F. Allegri. "The economic cost of Alzheimer's disease: Family or public-health burden?." *Dement Neuropsychol* 4 (2010): 262-267.
3. Lyketsos, Constantine G., Maria C. Carrillo, J. Michael Ryan and Ara S. Khachaturian, et al. "Neuropsychiatric symptoms in Alzheimer's disease." *Alzheimers Dement* 7 (2011): 532-539.
4. Teixeira, Antonio L., Mitzi M. Gonzales, Leonardo Cruz De Souza and Sara L. Weisenbach. "Revisiting apathy in Alzheimer's disease: From conceptualization to therapeutic approaches." *Behav Neurol* 2021 (2021): 1-8.
5. Aalten, Pauline, Frans RJ Verhey, Marina Boziki and Roger Bullock, et al. "Neuropsychiatric syndromes in dementia: Results from the European Alzheimer Disease Consortium: Part I." *Dement Geriatr Cogn Disord* 24 (2007): 457-463.
6. Nobis, Lisa and Masud Husain. "Apathy in Alzheimer's disease." *Curr Opin Behav Sci* 22 (2018): 7-13.

How to cite this article: Kenne, Sea. "Understanding the Neurobiological Basis of Schizophrenia through the Lens of Abnormal Psychology." *Abnorm Behav Psychol* 9 (2023): 211.